Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?
AffiliationClinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Healthcare Science Centre, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester, M20 4BX, UK. firstname.lastname@example.org.
MetadataShow full item record
AbstractThe central goal of cancer immunotherapy is to control tumors through the mobilization of the patient's immune system. Vaccines targeting the Her2/neu proto-oncogene have been tested with some early encouraging responses in breast cancer. However, a more effective set of vaccines targeting specific immune cell subtypes may provide a more potent means to stimulate anti-tumor immunity. Dendritic cell-specific antibodies fused with the Her2/neu protein proved effective at generating immune responses in preclinical models. Importantly, only low amounts of protein vaccine were required to generate this response, which has potentially significant implications for the future clinical development of Her2/neu-targeted vaccines and other vaccine targets.
CitationTargeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein? 2012, 14 (3):106 Breast Cancer Res
JournalBreast Cancer Research
- Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
- Authors: Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, Steinman RM
- Issue date: 2012 Mar 7
- Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
- Authors: Wang L, Xie Y, Ahmed KA, Ahmed S, Sami A, Chibbar R, Xu Q, Kane SE, Hao S, Mulligan SJ, Xiang J
- Issue date: 2013 Jul
- Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
- Authors: Xie Y, Wu J, Xu A, Ahmeqd S, Sami A, Chibbar R, Freywald A, Zheng C, Xiang J
- Issue date: 2018 Mar 7
- Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
- Authors: Kodumudi KN, Ramamoorthi G, Snyder C, Basu A, Jia Y, Awshah S, Beyer AP, Wiener D, Lam L, Zhang H, Greene MI, Costa RLB, Czerniecki BJ
- Issue date: 2019
- Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
- Authors: Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y
- Issue date: 2009 Jul 15